Drugs / SB4
SB4
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01865552 | May → Aug 2013 | — | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01895309 | Jun 2013 → Apr 2014 | rheumatoid arthritis | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01895309 ↗ |
| Known as | Benepali | “SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN).” PMID 28794078 ↗ Nov 2017 |
| Known as | Brenzys | “SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN).” PMID 28794078 ↗ Nov 2017 |
| Modality | Protein / enzyme biologic | “SB4 [an etanercept biosimilar]” PMID 28968793 ↗ Dec 2017 |
| Route | Subcutaneous | “SC administration” NCT01865552 ↗ |